Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), ARNA: 3.57 (-0.01)
3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.99 (+0.67), OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen Retreats After Positive News In Europe: 3 Things To Watch For
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:18PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
New Obesity Drug Available Soon
Brian Orelli, The Motley Fool - Motley Fool - Sun Dec 21, 9:22PM CST
Europeans will have a new option for treating their obesity shortly. The Committee for Medicinal Products For Human Use, or CHMP, gave Orexigen 's Mysimba a positive recommendation. Orexigen will have to wait for the European Commission to adopt...
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Arena And Vivus Investors Need To Grasp Implications Of Orexigen
Spencer Osborne - at Seeking Alpha - Fri Dec 19, 1:22PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators
at The Street - Fri Dec 19, 7:25AM CST
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Low-Cost Contrave Fuels Anti-Obesity Drugs Recovery From Thanksgiving
Clinically Sound Investor - at Seeking Alpha - Tue Dec 16, 12:50AM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Why Should Investors Expect Physicians To Treat Obesity With Pharmacotherapy?
Joseph Dedvukaj - Seeking Alpha - Mon Dec 15, 9:30AM CST
Until recently, the practice of primary care medicine seemed to ignore obesity as a primary disease and focus solely upon treating the complications of obesity. Appropriate guidelines and standards for treating Diabetes, Hypertension, Hyperlipidemia,...
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Zafgen starts clinical trial in severe obesity and type 2 diabetes
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:43AM CST
OREX: 5.98 (+0.01), ZFGN: 30.99 (+0.67), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Contrave Sales Continue To Impress
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:26PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Arena: Belviq Sales See Pleasant Rebound
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:05PM CST
OREX: 5.98 (+0.01), ARNA: 3.57 (-0.01)
Arena Pharmaceuticals (ARNA) Weak On High Volume Today
at The Street - Fri Dec 12, 9:01AM CST
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
ARNA: 3.57 (-0.01)
Assessing The Beginnings Of The Orexigen Launch Of Contrave
Spencer Osborne - at Seeking Alpha - Wed Dec 10, 12:09PM CST
OREX: 5.98 (+0.01), ARNA: 3.57 (-0.01)
Belviq Still Lacking Coverage At The Top, But Could Recover In The Exchanges
Clinically Sound Investor - at Seeking Alpha - Tue Dec 09, 7:02AM CST
ARNA: 3.57 (-0.01)